Key Accomplishments to Date

The Cancer Immunotherapy Consortium (formerly the Cancer Vaccine Consortium) has served the cancer immunotherapy community since 2002 and has made significant contributions to the recent progress in the field. Through seminars, workshops, and online consensus-building projects supported by immunological and clinical data from cancer immunotherapy trials, CIC members have worked with one another as well as with other international community organizations to address several of the key issues facing the field, including:

	Application of principles of chemotherapy to the clinical development of immunotherapies
	New clinical development paradigm for immunotherapies   J. Immunotherapy 2007

	Clinical trial endpoints focused on non-immunological standards
	Adjustment of endpoints to immunotherapy biology     Vaccine 2007   A second publication is in preparation (3/10)

	No system to measure all patterns of immunotherapy clinical activity
	Development of immune-related response criteria     Clinical Cancer Research 2009

	High data variability for immune monitoring in multi-center trials
	Harmonization guidelines and quality assurance for immune monitoring assays   Cancer Immunology Immunotherapy 2007    Cancer Immunology Immunotherapy 2009 See the  CIC ImmunoAssay Proficiency Panel Program for more details.

	Limited integration and distribution of key scientific and developmental knowledge
	Focused scientific exchange between academia, industry, and regulators through meetings and workshops

	Absence of regulatory guidance for cancer immunotherapy development
	Facilitation of broad scientific exchange including regulators to support guidance document development    View Comments

	Inconsistent reporting of immune monitoring results in publications
	Minimal Information About T-Cell Assays (MIATA) Reporting Framework    Go to the MIATA Project Web site

Return to the Cancer Immunotherapy Consortium main page